JUPITER NEUROSCIENCES, INC.

Jupiter Neurosciences is a clinical-stage biotechnology company focused on developing resveratrol-based pharmaceutical candidates to treat neuroinflammatory and neurodegenerative diseases. The company's pipeline includes five programs currently in Phase II trials: JNS101 for Friedreich's Ataxia, JNS108 for mild cognitive impairment and early Alzheimer's disease, JNS102 for mucopolysaccharidosis type 1, JNS107 for mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome, and JNS115 for Parkinson's disease. The company also operates JNS115 in a Phase IIa trial through a partnership with Zina Biopharmaceuticals to evaluate the safety and tolerability of resveratrol in Parkinson's disease patients.

Jupiter Neurosciences maintains strategic partnerships to expand its development efforts and commercial reach. The company collaborates with Aquanova AG on consumer-focused nutritional products targeting longevity, aging, and healthspan applications. The company is incorporated in Delaware and headquartered in Jupiter, Florida. With four full-time employees, Jupiter Neurosciences operates as a lean, pre-revenue clinical-stage entity typical of early biotechnology firms.